Ubiquity of the SARS-CoV-2 receptor ACE2 and upregulation in limbic regions of Alzheimer’s disease brain

Yuhai Zhao1,2, Wenhong Li1,3, Walter J. Lukiw1,4,5
1LSU Neuroscience Center, Louisiana State University Health Sciences Center, New Orleans, LA, USA, 2Department of Anatomy and Cell Biology, LSU Health Sciences Center, New Orleans, LA, USA, 3Department of Pharmacology, School of Pharmacy, Jiangxi University of TCM, Nanchang, Jiangxi, China, 4Department of Ophthalmology, Louisiana State University Health Sciences Center, New Orleans, LA, USA, 5Department of Neurology, Louisiana State University Health Sciences Center, New Orleans LA, USA


Abstract
The major route of entry for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) into human host cells is by means of the angiotensin-converting enzyme-2 (ACE2) transmembrane receptor. This zinc-containing carboxypeptidase and membrane-integral surface receptor is ubiquitous and widely expressed in multiple cell types. Hence SARS-CoV-2, an unusually large RNA virus that causes coronavirus disease 2019 (COVID-19) has the remarkable capacity to invade many different types of human host cells simultaneously. Although COVID-19 is generally considered to be primarily an acute respiratory disease SARS-CoV-2 also targets specific anatomical regions of the central nervous system (CNS). In the normal CNS the highest ACE2 levels of expression are found within the medullary respiratory centers of the brainstem and this, in part, may explain the susceptibility of numerous COVID-19 patients to severe respiratory distress. About ~35% of all COVID-19 patients experience neurological and neuropsychiatric symptoms, and a pre-existing diagnosis of Alzheimer’s disease (AD) predicts the highest risk of COVID-19 yet identified, with the highest mortality among elderly AD patients. In the current study of multiple anatomical regions of AD brains compared to age-, post-mortem interval- and gender-matched controls (n = 10 regions, n = 32 brains), ACE2 expression was found to be significantly up-regulated in AD in the occipital lobe, temporal lobe neocortex and hippocampal CA1. The temporal lobe and hippocampus of the brain are also targeted by the inflammatory neuropathology that accompanies AD, suggesting a significant mechanistic overlap between COVID-19 and AD, strongly centered on invasion by the neurotropic SARS-CoV-2 virus via the increased presence of ACE2 receptors in limbic regions of the AD-affected brain.

Key words: Alzheimer’s disease, angiotensin-converting enzyme 2 (ACE2) receptor, Botzinger complex, COVID-19, coronavirus, SARS-CoV-2, single stranded RNA (ssRNA), TMPRSS2.

Introduction
The coronavirus disease pandemic, named COVID-19 by the World Health Organization (WHO), originated in late 2019 in an open air market in the city of Wuhan, Hubei Province in east-central China [1-3]. Initial reports suggested that the emergence of the novel SARS-CoV-2 virus, the causative agent of COVID-19, may have occurred via ‘zoonotic spillover’ from the fruit bat (Pteropus scapulatus), the Chinese...
pangolin (Manis pentadactyla) and/or other mammalian vectors through interspecies viral transmission [1,10,13,21,25,32]. To date over ~162 million cases of COVID-19 have been reported worldwide with over ~3.4 million deaths at the time of the writing of this report [13,29].

Of COVID-19 patients and survivors many report an extremely wide array of respiratory, sensorial and neurological symptoms including intermittent loss of respiratory control, loss of taste (ageusia) and smell (anosmia), disruption in the coordination of movement (ataxia), loss of balance (vertigo), dizziness and light-headedness (presyncope), headache and nausea, direct negative effects of a heightened immune reaction and unusual hyper-inflammatory responses as a consequence of a prolonged ‘cytokine storm’, with indications of increased cardiovascular and neurovascular pathology and symptoms of an exacerbation or de novo induction of inflammatory neurodegeneration [2,3,34,36]. In addition there are widely reported progressive disturbances in cognition, anxiety and intermittent impairment or loss of consciousness, acceleration or aggravation of pre-existing cognitive deficits including a long-lasting ‘brain fog’ and a persistent and continuing disruption in understanding, reasoning and memory [2,17,19,20,22,34-36]. These deficits suggest the potential involvement of specific anatomical regions of the brain involved in perception, memory processing and cognition strikingly similar to those same brain areas targeted by Alzheimer’s disease (AD). To cite 4 recent examples: (i) in the analysis of primary health records for over ~13,300 UK individuals tested for COVID-19 between March and July 2020 it was shown that a pre-existing diagnosis of AD predicted the highest risk of COVID-19 yet found, driving the highest mortality rate amongst any classification of aged individuals [16,33]; (ii) the morbidity and mortality of COVID-19 are elevated in AD due to multiple pathological changes in AD patients such as the excessive expression of the ACE-2 receptor and pro-inflammatory cytokines and chemokines, various ancillary complications of AD including cardiovascular and neurovascular disease, diabetes, delirium and lifestyle alterations in AD [30]; (iii) multiple COVID-19 patients have reported various neurologic symptoms including AD-type cognitive impairment in part through COVID-19-induced inflammation, and post-COVID-19 syndrome [8]; and (iv) infection by SARS-CoV-2 both increases physiological and psychological stress and aggravates inflammatory reactions including the ‘cytokine storm’, supporting the deterioration of neuronal function and accelerating the progression of AD [8,18].

Two previous reports of increased angiotensin-converting enzyme-2 (ACE2) expression in AD have appeared in the literature, however they were both limited studies involving only one brain region and/or post-mortem intervals (PMIs) of brain tissues > 13 hours [4,11]. In the present report we have analyzed the protein levels of ACE2 and human transmembrane protease, serine 2 (TMPRSS2), an ACE2 cellular serine protease that facilitates cellular SARS-CoV-2 entry [23], in 10 brain regions from 32 control and AD brains with mean PMIs of 3.1-3.2 hours for all tissue samples analyzed. This is the first report of multiple regions of expression of the SARS-CoV-2 entry protein ACE2 and TMPRSS2 in limbic regions of the brain known to be involved in cognition and memory, which are the same anatomical regions targeted by the AD process. While TMPRSS2 protein showed no significant change in abundance between control and AD when the same anatomical area was compared, ACE2 receptor protein abundance was found to be significantly elevated in the occipital pole (Brodmann area 17; the primary visual cortex), the temporal lobe neocortex (Brodmann area 22) and the hippocampal CA1 region. The latter two anatomical regions comprise a major part of the brain’s limbic system normally involved in the processing of emotion, behavior, olfaction, cognition and memory.

**Material and methods**

**Human brain tissues**

Total protein was extracted from about ~20 mg (wet weight) samples of 9 control and 23 AD post-mortem human brains; post-mortem human brain tissues of the highest quality available were obtained from 18 domestic and international brain banks (listed in the Acknowledgements section); the mean post-mortem interval (PMI; brain-death to brain-freezing at −81°C) ± one standard deviation was 3.1 ±1.1 hours for control and 3.3 ±1.4 hours for AD; the mean age of the brain tissue donors was 76.3 ±12.4 year for control and 78.1 ±11.7 year for AD brain samples; there were no significant differences between the PMI, age or gender between the control and AD groups. All tissues were from female donors.
Ten brain regions including the cerebellum, thalamus, hypothalamus, pons, medulla oblongata, parietal lobe (Brodman area 9), parietal lobe (Brodman area 5), occipital lobe (Brodman area 17; primary visual cortex), temporal lobe (Brodman area 22; association neocortex) and the hippocampal CA1 region were extracted and processed as previously described [12]. The original CERAD (Center to establish a registry for Alzheimer’s disease)/National Institutes of Health criteria were used to categorize AD tissues in accordance with established guidelines [15]. All brain tissues were banked between 2015 and 2020 using the original CERAD criteria, and all of the AD tissues used in these studies had a clinical dementia rating (CDR) of 2.0-3.0, indicating the moderate- to severe stage of this progressive, age-related neurological disorder.

**ACE2 and TMPRSS2 protein analysis**

Protein extracts from control or AD tissues were generated using a ProteoExtract Complete Mammalian Proteome Extraction Kit (cat. no. 539779, Calbiochem/Millipore-Sigma Burlington MA) and were assayed for protein concentration using a Non-Interfering Protein Assay kit (cat. no. 488250, Calbiochem/Millipore-Sigma; quantified at 480 nm); protein samples were stored in at −81°C according to the manufacturer’s protocol (Millipore-Sigma); ACE2 protein [UniProtKB – Q9BYF1 (ACE2_HUMAN)] [7,27] and TMPRSS2 protein [UniProtKB – O15393 (TMP2S_HUMAN)] [27,28] abundance in these cell extracts of human brain regions were analyzed using a quantitative colorimetric (450 nm) sandwich ELISA specific for human ACE2 or TMPRSS2 employing a Fluoroskan Ascent FL Microplate Fluorometer and Luminometer (cat. no. 5200220, ThermoFisher Scientific, Waltham MA); we utilized a human ACE2 ELISA Kit ab235649; Abcam Cambridge MA, USA; sensitivity 59 pg/ml; detection range 0.156-10 ng/ml and a human (human transmembrane protease, serine 2 (TMPRSS2) ELISA Kit, cat. no. EKN48965 96T/ cat. no. EKU07854; Biomatik Wilmington DE; sensitivity 1052 pg/ml; detection range 1.5-255 ng/ml and a human (human β-actin antibody (Abcam ab8227) were used as internal controls to quantify relative ACE2, TMPRSS2 and β-actin protein abundance in each sample according to the manufacturer’s instructions (Fig. 1); concentrations of ACE2, TMPRSS2 and β-actin were measured in tripli-
cate and quantified according to the manufacturer's protocol (Supplementary File 1).

**Statistical analysis**

The analysis of statistical significance was evaluated using a two-way factorial analysis of variance (p, ANOVA; SAS Institute, Cary NC, USA). A \( p < 0.05 \) (ANOVA) was deemed as statistically significant; a \( p < 0.01 \) (ANOVA) was deemed as very highly significant; experimental values were expressed as the means ± one standard deviation (SD) of that mean (Fig. 1).

**Results**

Both ACE2 and TMPRSS2 proteins were abundantly detected in all 10 anatomical regions of the brain examined in this study. As determined by ELISA the mean abundance for the 805 amino acid 92.5 kDa ACE2 protein was about ~15 ng/ml extract and the mean abundance of TMPRSS2 protein was about ~1.6 ng/ml; in both cases 20 mg wet weight of brain tissue were extracted using the protocol described above; the ACE2 receptor is therefore among the most abundant receptor types on the surface of human brain cells [7,13,27]. As quantified by ELISA there was no significant difference in the abundance of the 492 amino acid, 53.9 kDa TMPRSS2 protein between control and AD in any of these same 10 anatomical regions of the brain examined (Supplementary File 1). On the other hand ACE2 was significantly increased in the occipital lobe (Brodmann area 17; the primary visual cortex), temporal lobe (Brodmann area 22; association neocortex) and hippocampal CA1 to respectively 2.05-fold, 2.25-fold and 3.25-fold over age-, gender- and PMI-matched controls (Fig. 1). No significant changes for ACE abundance in the cerebellum, thalamus, hypothalamus, pons, medulla oblongata, frontal lobe (Brodmann area 9) or parietal lobe (Brodmann area 5) were noted in any of the AD tissues analyzed compared to controls [13,16].

**Discussion**

The invasion of SARS-CoV-2 into human host cells occurs via the ACE2 receptor that is absolutely essential for viral infectivity and intracellular replication [3,5,16,36]. Accessory membrane enzymes such as the serine 2 transmembrane protease TMPRSS2 facilitates SARS-CoV-2 infection via two independent mechanisms, proteolytic cleavage of monooxypeptidase ACE2 at the intracellular C-terminal endodomain which promotes viral uptake, and cleavage of coronavirus spike (S1) glycoprotein which activates S1 for host cellular entry [5,7,24]. Besides enabling SARS-CoV-2 invasion, the ubiquitous ACE2 receptor is normally involved in the renin-angiotensin system (RAS), and functions in vasoconstriction and vasodilation, as a critical regulator of blood pressure, blood volume, systemic vascular resistance, amino acid trafficking and cardiovascular and neurovascular homeostasis [5,23,24,27]. The upregulation of ACE2, but not TMPRSS2, in anatomical regions involved in AD again underscores ACE2's importance as a key facilitator of SARS-CoV-2 infection in brain areas targeted for age-related neurodegeneration. The omnipresence of ACE2 expression in multiple human cell-, tissue-types and brain regions is noteworthy, and the elicitation of this SARS-CoV-2-mediated multipronged attack explains in part the severity and extensive variety of signs and symptoms widely observed in COVID-19 patients.

The SARS-CoV-2 virus has evolved a remarkable evolutionary strategy to ensure its replication, survival, proliferation and propagation by exploiting the presence of a very common, abundant, essential and susceptible transmembrane ACE2 receptor making many different neural and extra-neural human cell- and tissue-types at high risk and susceptibility to SARS-CoV-2 invasion. Another feature is that COVID-19 preferentially affects those patients with pre-existing medical conditions, such as a compromised immune and metabolic systems and those with neurological disorders that include AD. Besides strong ACE2 expression in respiratory epithelium, digestive, renal-excretory and reproductive cells, high ACE2 expression has also been found in the AD-affected limbic regions of the brain including the temporal association neocortex and hippocampal structures [13]. Elevated ACE2 levels in anatomical regions of the brain centrally involved in AD-type change suggests a significant mechanistic overlap between AD and COVID-19 strongly centered on invasion by the neurotropic SARS-CoV-2 via the ubiquity and overexpression of ACE2 receptors and their close association with inflammatory neurodegeneration. After the acute phase of COVID-19 infection and prospective recovery, the long-term neurological complications of SARS-CoV-2 neuroinvasion on the development of age-related neurodegenerative dis-
orders are still not well understood [6,31]. COVID-19 is an acute condition while AD is age-related and a disorder of the elderly, so it may be some time before the opportunity arises to examine SARS-CoV-2-triggered neuropathological changes in a large number of post-mortem AD-affected human brains in order to obtain statistical strength for more robust correlation analysis [6,16,17,31,33,35].

Summary

The current COVID-19 pandemic (i) has created an unparalleled global health crisis; and (ii) our scientific understanding of the mechanistic factors involved in SARS-CoV-2 transmission, invasion, viral spread and affinity for multiple human host cell targets continues to evolve. The ACE2 receptor, the gateway for SARS-CoV-2 entry into the host cell, has an extraordinary ubiquity and has been detected on the surface of all human cell types analyzed so far (with the exception of the erythrocyte) thus making it among the most prevalent receptor subtypes encountered in the human body. This indicates (i) that multiple cell types and tissues of the human respiratory, cardiovascular, digestive and genitourinary systems, hematic, lymphatic and glymphatic systems, and the central and peripheral nervous systems (CNS, PNS) provide many different potential entry portals for SARS-CoV-2 invasion; and (ii) this may in part explain the wide range of systemic involvement of SARS-CoV-2 infection and the variation in the many symptoms observed in both active and recovering COVID-19 patients. Abundant data further indicate that the high abundance of ACE2 in different brain cell types and neuroanatomical regions have a bearing on the widely reported incidence of disorientation, impairment of memory, reasoning and cognition and ‘brain fog’ not only during active SARS-CoV-2 disease but also during the often challenging period of recuperation following COVID-19 infection.

The following are related to these observations: (i) SARS-CoV-2 directly infects human neurons [23,24]; and (ii) the highest ACE2 receptor abundance in the normal CNS has been found in the pons and medulla oblongata of the lower human brainstem that contain the medullary respiratory regulatory rhythm generators, including the Botzinger complex that regulates inspiration during respiratory activity, and this in part may explain the susceptibility of numerous COVID-19 patients to severe respiratory distress [13,33]. Another remarkable finding is the neurotropism of SARS-CoV-2 towards highly specific brain regions involved in memory and cognition that are also targeted by the inflammatory neurodegeneration characteristic of that observed in AD brain [6,12]. The highest density of the ACE2 receptors in the brain colocalize to areas also targeted by AD including the occipital lobe containing the primary visual cortex and the temporal lobe and hippocampal CA1, key anatomical regions involved in visual perception and interpretation and the limbic system collectively involved in visual signal processing, cognition, behavior and memory formation [6,31]. It has been shown recently that a pre-existing diagnosis of AD predicts the highest risk yet found for the development of COVID-19, and is further associated with the highest mortality rate among adults > 65 years of age – these constitute a very high-risk elderly group prone to the most severe cases of SARS-CoV-2 often with a lethal outcome [16,17,31]. Our current healthcare system could be faced with a significantly increased volume of AD patients dealing with these and other associated issues of neurological comorbidity in older adults after the most severe cases of SARS-CoV-2 infection, requiring long-term neurological follow-up in the often difficult aftermath of COVID-19 recovery.

Acknowledgements

The experimental, analytical and statistical work in this communication was presented in part at the Society for Neuroscience (SFN) online Annual Meeting on 19-23 October 2019 in Chicago IL, USA. Sincere thanks are extended to the late Drs. JM Hill (JMH; Louisiana State University) for helpful discussions on this research area and to F. Culicchia, C. Eicken, C. Hebel, B. Krishnan, K. Navel, and L Wong for short postmortem interval (PMI) human and other mammalian brain tissues or extracts and to D. Guillot and A.I. Pogue for expert technical assistance. Thanks are also extended to the many neuropathologists, physicians and researchers of the US, Canada, Europe and the Russian Federation who have provided high quality, short postmortem interval (PMI) human CNS or extracted brain tissue fractions for scientific study. We would like to further thank the following 18 domestic and international brain banks, and their continuing cooperation, for access to high quality short PMI tissues and valuable analytical advice: the Autism Brain Net, Los Angeles,
ACE2 receptor expression in Alzheimer's disease

CA, USA; the Harvard University/McLean Hospital Tissue Center, Boston, MA, USA; Louisiana State University, New Orleans, LA, USA; the Lomonosov Institute, Moscow State University, Moscow, Russian Federation; the National Disease Research Interchange, Philadelphia, PA, USA; the National Institutes of Health NIH NeuroBioBank, comprised of tissues from the National Institute of Mental Health (NIMH), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA; the Netherlands Brain Research Institute, Amsterdam, Netherlands; the New York State Institute for Basic Research, Staten Island, NY, USA; the Oregon Health Sciences University, Portland, OR, USA; the Southern Eye Bank, Metairie, LA, USA; the University of California, Irvine, CA, USA; the University of Kentucky Alzheimer’s disease Brain Bank, Lexington, KY, USA; the University of Maryland Brain and Tissue Bank, Baltimore, MD, USA; the University of Massachusetts, Worcester, MA, USA; University of Pennsylvania School of Medicine, Philadelphia, PA, USA, and the University of Toronto Brain Bank, Toronto, ON, Canada. All authors agree on the content of this publication. Research on metal neurotoxicity, human and murine microRNAs, small noncoding RNA (sncRNA), proinflammatory and pathogenic signaling in the Lukiw laboratory involving the innate-immune response, amyloidogenesis and inflammatory neurodegeneration in AD, ASD, PrD and in other human neurological disorders was supported through an unrestricted grant to the LSU Eye Center from Research to Prevent Blindness (RPB); the Louisiana Biotechnology Research Network (LBRN), the National Institutes of Health (NIH), Bethesda, MD, USA and the Alzheimer Association Chicago, IL, USA.

Ethics statement

All acquisition, handling, experimental and analytical procedures involving postmortem human brain tissues were carried out in an ethical manner in strict accordance with the ethics review board policies at brain and tissue donor institutions and at the Louisiana State University (LSU) Health Sciences Center. Informed consent from next of kin was obtained at brain and tissue donor institutions for all tissue samples prior to autopsy and donation; coded postmortem brain tissue samples (containing no personal identifying information of the donors) were obtained from the 18 brain and tissue banks listed in the Acknowledgements section above. The ethical use of postmortem human brain tissues and their analyses were also carried out in strict accordance with the Institutional Biosafety Committee and the Institutional Review Board Committee (IBC/IRBC) ethical guidelines IBC#18059 and IRBC#6774 at the LSU Health Sciences Center, New Orleans, LA 70112, USA.

Disclosure

The authors report no conflict of interest. The experimental work in this paper was funded by the LSU Eye Center from Research to Prevent Blindness (RPB), the Louisiana Biotechnology Research Network (LBRN), the National Institutes of Health (NIH), Bethesda, MD, USA and the Alzheimer Association Chicago, IL, USA.

The supplementary file 1 is available on journal website.

References


27. www.uniprot.org/uniprot/Q9BYF1; ACE2 – Angiotensin-converting enzyme 2 precursor – Homo sapiens (Human) – ACE2 gene & protein (uniprot.org) UniProtKB – Q9BYF1 (ACE2_HUMAN); last accessed 23 August 2021.


